Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Open-label Study Of The Safety And Efficacy Of Pd 0332991 In Combination With Bortezomib And Dexamethasone In Patients With Refractory Multiple Myeloma

NCT00555906 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00555906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00555906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Open-label Study Of The Safety And Efficacy Of Pd 0332991 In Combination With Bortezomib And Dexamethasone In Patients With Refractory Multiple Myeloma
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
March 31, 2013
Enrollment
53 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma